Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAG104615 Proof of Concept Study for GSK249320 in Ischemic Stroke
2010-024087-17Phase 2Terminated
- Sponsor
- GSK
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing GSK249320 with Placebo (2 arms). Primary endpoint: Lower limb motor recovery (locomotion). Started Aug 2011; status: terminated.
02
Drugs
refanezumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2010-024087-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024087-17.